Compare · CMPI vs NPT
CMPI vs NPT
Side-by-side comparison of Checkmate Pharmaceuticals Inc. (CMPI) and Texxon Holding Limited (NPT): market cap, price performance, sector, and recent activity on the wire.
Summary
- CMPI operates in Consumer Durables, while NPT operates in Consumer Discretionary - the two are in different parts of the market.
- NPT carries a market cap of $41.5M.
- NPT has hit the wire 1 time in the past 4 weeks while CMPI has been quiet.
- CMPI has more recent analyst coverage (1 ratings vs 0 for NPT).
- Company
- Checkmate Pharmaceuticals Inc.
- Texxon Holding Limited
- Price
- -
- -
- Market cap
- -
- $41.5M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Specialty Chemicals
- Specialty Chemicals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2025
- News (4w)
- 0
- 1
- Recent ratings
- 1
- 0
Checkmate Pharmaceuticals Inc.
Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Latest CMPI
- Axonis Therapeutics Announces $115 Million Series A Financing
- venBio Raises $528 Million Venture Capital Fund Focused on Life Science Companies
- SEC Form 15-12B filed by Checkmate Pharmaceuticals Inc.
- SEC Form SC 13G/A filed by Checkmate Pharmaceuticals Inc. (Amendment)
- SEC Form SC 13D/A filed by Checkmate Pharmaceuticals Inc. (Amendment)
- SEC Form SC 13D/A filed by Checkmate Pharmaceuticals Inc. (Amendment)
- SEC Form SC 13D filed by Checkmate Pharmaceuticals Inc.
- SEC Form EFFECT filed by Checkmate Pharmaceuticals Inc.
- Completion of the Acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals Triggers $2.5M Milestone Payment to XOMA
- SEC Form 25-NSE filed by Checkmate Pharmaceuticals Inc.
Latest NPT
- SEC Form NT 20-F filed by Texxon Holding Limited
- Texxon Holding Limited Announces Commencement of Operations at Henan Polystyrene Production Facility, A Milestone in Manufacturing Expansion Strategy
- SEC Form 6-K filed by Texxon Holding Limited
- Texxon Holding Limited Announces Unaudited Financial Results for the First Half of Fiscal Year 2026
- SEC Form 6-K filed by Texxon Holding Limited
- SEC Form 6-K filed by Texxon Holding Limited
- Texxon Holding Limited Announces Annual General Meeting
- SEC Form 3 filed by new insider Xu Hui
- SEC Form 3 filed by new insider Huang Jian (Hanke)
- SEC Form 3 filed by new insider Qin Lei